Verification evidence is still being completed.
PDF / print export
Galecto, Inc.
Copenhagen, Denmark
- Verified lead
- Hans Schambye
- Lead status
- STATUS: VERIFIED APRIL 2026
- Leadership verification
- Chief Executive Officer
- 2026 technical specialization
- Galectin-3 and LOXL2 Small-Molecule Inhibitors for Fibrosis, Oncology, and Inflammation
- Review cycle
- 24 April 2026
- Full address
- Ole Maaloes Vej 3, COBIS Science Park, 2200 Copenhagen, Denmark
- Site coordinates
- Verification evidence is still being completed.
- Editorial review
- Memel Biotech editorial review
- Official leadership source
- Galecto investor relations page naming Hans Schambye as Chief Executive Officer.
- Editorial note
- Nasdaq-listed (GLTO) clinical-stage Danish-US biotech with named CEO, a galectin-3 and LOXL2 inhibitor pipeline, and a Copenhagen operating headquarters at COBIS.
Galectin-3 and LOXL2 Small-Molecule Inhibitors for Fibrosis, Oncology, and Inflammation
Nasdaq GLTO listing, Public investor-relations CEO disclosure, Clinical-stage program documentation
Nasdaq-listed (GLTO) clinical-stage Danish-US biotech with named CEO, a galectin-3 and LOXL2 inhibitor pipeline, and a Copenhagen operating headquarters at COBIS.
Review coverage
Leadership
Facility
Certifications
Capabilities
Partners
Sources
Quality
Editorial verificationMemel Biotech directory review sign-off
Report generated02 Jun 2026, 01:40
Company profile · Copenhagen, Denmark
Galecto, Inc.
Galectin-3 and LOXL2 Small-Molecule Inhibitors for Fibrosis, Oncology, and Inflammation · Clinical-stage small-molecule development
Nasdaq-listed (GLTO) clinical-stage Danish-US biotech with named CEO, a galectin-3 and LOXL2 inhibitor pipeline, and a Copenhagen operating headquarters at COBIS.
- Lead
- Hans Schambye (verified ↗)
- Address
- Ole Maaloes Vej 3, COBIS Science Park, 2200 Copenhagen, Denmark (source ↗)
- Compliance
- Not yet on record
- Last reviewed
- 24 Apr 2026 (1mo ago)
- Scale
- Clinical-stage small-molecule development
- Capabilities
- Galectin-3 Inhibitor Discovery · LOXL2 Inhibitor Development · Clinical-Stage Small-Molecule Operations
- Founded
- 2011
- Headcount
- 11-50
- Company page (open ↗)
Clinical profileSTATUS: VERIFIED APRIL 2026
Hans Schambye
Chief Executive Officer
Full addressOle Maaloes Vej 3, COBIS Science Park, 2200 Copenhagen, Denmark
Site coordinatesVerification evidence is still being completed.
Review cycle24 April 2026
Physical site source
Life Sciences Europe profile listing Galecto Biotech at COBIS Copenhagen.
Open sourceClinical-stage small-molecule development
Copenhagen, Denmark. Galectin-3 and LOXL2 Small-Molecule Inhibitors for Fibrosis, Oncology, and Inflammation. Review completed on 24 Apr 2026.
Danish Medicines Agency, EMA, and FDA for clinical trials
Nasdaq GLTO listing, Public investor-relations CEO disclosure, Clinical-stage program documentation
Galectin-3 and LOXL2 Small-Molecule Inhibitors for Fibrosis, Oncology, and Inflammation
Nasdaq-listed (GLTO) clinical-stage Danish-US biotech with named CEO, a galectin-3 and LOXL2 inhibitor pipeline, and a Copenhagen operating headquarters at COBIS.
Editorial note
Galecto is US-incorporated but operates from the COBIS science park in Copenhagen, with a named CEO since 2011, Nasdaq listing (GLTO), and a pipeline centred on galectin-3 and LOXL2 inhibition.
FULL TRUST REVIEW COMPLETE
Shown only when all seven trust checks are fully mapped in the directory.
Current review cycleApril 2026
Capabilities
Core capabilities
Primary declared technical activities and areas of operating focus.
Galectin-3 Inhibitor Discovery
LOXL2 Inhibitor Development
Clinical-Stage Small-Molecule Operations
Verification source dossier
Verification source dossier
Official source set used to support leadership, physical-site, certification, and watch-note evidence.
Infrastructure
Declared infrastructure
Small-molecule discovery platform
Clinical trial operations
Partner CDMO supply chain
Regulatory posture
Quality system coverage
GMP / GLP / ISO-13485 / FDA-Inspected are global quality-system standards. "Verified active" means the directory confirmed the certification is current; "Review in progress" means the cert status is currently being re-verified.
- GMP
- REVIEW IN PROGRESS 2026
- GLP
- REVIEW IN PROGRESS 2026
- ISO-13485
- REVIEW IN PROGRESS 2026
- FDA-Inspected
- REVIEW IN PROGRESS 2026
Verification history
Verification history
24 Apr 2026: Executive identity confirmed via official management disclosure.
24 Apr 2026: Full trust review completed.
FAQ
Frequently asked questions
- Where is Galecto, Inc. located?
- Galecto, Inc. operates from Ole Maaloes Vej 3, COBIS Science Park, 2200 Copenhagen, Denmark, Copenhagen, Denmark.
- Who runs Galecto, Inc.?
- Galecto, Inc. is led by Hans Schambye, Chief Executive Officer. Verified 24 Apr 2026.
- What does Galecto, Inc. do?
- Nasdaq-listed (GLTO) clinical-stage Danish-US biotech with named CEO, a galectin-3 and LOXL2 inhibitor pipeline, and a Copenhagen operating headquarters at COBIS. Core capabilities: Galectin-3 Inhibitor Discovery, LOXL2 Inhibitor Development, Clinical-Stage Small-Molecule Operations.
Editorial context
Related technical briefs
Briefs that name Copenhagen as a covered market or city.